Jeffrey Cohen
Internal Medicine · San Diego, CANPI 1184184251
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 42 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 12.1% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $455, 2.8 times the $164 reported in 2023.
Across 42 payments — averaging $23.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$117
- Pfizer$110
- Lilly USA, LLC$101
- AbbVie$95
- Boehringer Ingelheim$70
- Abiomed$63
- plus $414 from 14 others
What the payments were for
- Food & beverage$972100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 5 | $117 |
| Pfizer | 5 | $110 |
| Lilly USA, LLC | 4 | $101 |
| AbbVie | 4 | $95 |
| Boehringer Ingelheim | 3 | $70 |
| Abiomed | 3 | $63 |
| Boston Scientific | 1 | $56 |
| Sanofi-aventis U.S. LLC | 3 | $50 |
| Merz Pharmaceuticals, LLC | 1 | $43 |
| Novo Nordisk | 2 | $38 |
| Seqirus USA Inc | 2 | $33 |
| Johnson & Johnson | 1 | $32 |
| Alnylam Pharmaceuticals Inc. | 1 | $28 |
| Si-bone, Inc. | 1 | $25 |
| Dexcom, Inc. | 1 | $24 |
| Amgen | 1 | $20 |
| Otsuka America Pharmaceutical, Inc. | 1 | $19 |
| Halozyme Inc | 1 | $16 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| Cranial Technologies, Inc | 1 | $13 |
How this compares
$972 in reported general payments places this provider in the 75th percentile of 13,581 internal medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Tamsulosin Hcl | 32 | $617 |
| Atorvastatin Calcium | 59 | $549 |
| Levothyroxine Sodium | 24 | $448 |
| Omeprazole | 14 | $442 |
| Pantoprazole Sodium | 19 | $325 |
| Lisinopril | 25 | $323 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 11 | $235 |
| Amlodipine Besylate | 27 | $233 |
| Fluticasone Propionate | 19 | $224 |
| Gabapentin | 19 | $214 |
| Rosuvastatin Calcium | 19 | $198 |
| Hydrochlorothiazide | 13 | $187 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 11 | $180 |
| Trazodone Hcl | 19 | $169 |
| Simvastatin | 11 | $138 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in San Diego
- Hatim HusainSan Diego$2M
- Steven EdelmanSan Diego$863K
- Christian RamersSan Diego$675K
- Adam ZweigSan Diego$421K
- James BreitmeyerSan Diego$227K
- Andrew ChengSouth San Francisco$55.1M
- Tung NgoNewport Beach$4.9M
- Christian EversullStanford$2.9M
- Christian SandrockSacramento$2.1M
- Teck LingPalo Alto$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.